



## ASX ANNOUNCEMENT

### Actinogen presentation to ASX small & mid-caps conference

**Sydney, 26 March 2025.** Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that its CEO, Dr Steven Gourlay, will be a speaker this afternoon at the ASX small & mid-caps conference in Sydney.

Dr Gourlay’s presentation is titled *Oral Xanamem® (emestedastat) Controlling brain cortisol to slow progression in Alzheimer’s disease and treat depression: enrolling pivotal Phase 2b/3 trial in Alzheimer’s*. The presentation outlines the attractive therapeutic profile of ACW’s novel small molecule drug Xanamem and provides an update as the company approaches critical milestones in its phase 2b/3 Alzheimer’s trial.

Register to join online using the following link: <https://www.asx.com.au/investors/investment-tools-and-resources/events/smld>

**Dr Gourlay’s conference presentation is attached to this announcement.**

ENDS

#### Investors

**Dr. Steven Gourlay**  
CEO & Managing Director  
P: +61 2 8964 7401  
E: [steven.gourlay@actinogen.com.au](mailto:steven.gourlay@actinogen.com.au)

**Michael Roberts**  
Investor Relations  
M: +61 423 866 231  
E: [michael.roberts@actinogen.com.au](mailto:michael.roberts@actinogen.com.au)

#### Media

**George Hazim**  
Media & Public Affairs Australia  
M: +61 417 516 262  
E: [georgehazim@mediaaffairs.com.au](mailto:georgehazim@mediaaffairs.com.au)

***Announcement authorised by the Board of Directors of Actinogen Medical***

#### About Actinogen Medical

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health.

Cognitive function means how a person understands, remembers and thinks clearly. Cognitive functions include memory, attention, reasoning, awareness and decision-making.

Actinogen is currently developing its lead compound, Xanamem, as a promising new therapy for Alzheimer’s Disease and Depression and hopes to study Fragile X Syndrome and other neurological and psychiatric diseases in the future. Reducing cortisol inside brain cells could have a positive impact in these and many other diseases. The cognitive dysfunction,

© Xanamem is a registered trademark of Actinogen Medical Limited

behavioural abnormalities, and neuropsychological burden associated with these conditions is debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

### **Clinical Trials**

The **XanaMIA Phase 2b/3 Alzheimer's disease trial** is a double-blind, 36-week treatment, placebo-controlled, parallel group design trial in 220 patients with mild to moderate AD and progressive disease, determined by clinical criteria and confirmed by an elevated level of the pTau181 protein biomarker in blood. Patients receive Xanamem 10 mg or placebo, once daily, and its ability to slow progression of Alzheimer's disease is assessed with a variety of endpoints. The primary endpoint of the trial is the internationally-recognized CDR-SB (Clinical Dementia Rating scale – Sum of Boxes). The trial is being conducted in Australia and the US. Initial results from an interim analysis of the first 100 participants are anticipated in Q4 2025 and final results H2 2026.

The **XanaCIDD Phase 2a depression trial** was a double-blind, six-week proof-of-concept, placebo-controlled, parallel group design trial in 167 patients with moderate, treatment-resistant depression and a degree of baseline cognitive impairment. Participants were evenly randomized to receive Xanamem 10 mg once daily or placebo, in most cases in addition to their existing antidepressant therapy, and effects on cognition and depression were assessed. Trial results were reported in August 2024 and showed clinically and statistically significant benefits on depression symptoms with positive effects on the MADRS scale (a validated scale of depression symptom measurement) and the PGI-S (a valid patient reported assessment of depression severity). Cognition improved markedly and to a similar extent in both Xanamem and placebo groups.

### **About Xanamem (emestedastat)**

Xanamem's novel mechanism of action is to control the level of cortisol in the brain through the inhibition of the cortisol synthesis enzyme, 11 $\beta$ -HSD1, without affecting production of cortisol by the adrenal glands. Xanamem is a first-in-class, once-a-day pill designed to deliver high levels of cortisol control in the brain.

Chronically elevated cortisol is associated with progression in Alzheimer's Disease and excess cortisol is known to be toxic to brain cells. Cortisol itself is also associated with depressive symptoms and when targeted via other mechanisms has shown some promise in prior clinical trials. The recent XanaCIDD trial demonstrated clinically and sometimes statistically significant benefits on depressive symptoms.

The Company has studied 11 $\beta$ -HSD1 inhibition by Xanamem in approximately 400 volunteers and patients in eight clinical trials. Xanamem has a promising safety profile and has demonstrated clinical activity in patients with depression, patients with biomarker-positive Alzheimer's disease and cognitively normal volunteers. High levels of target engagement in the brain with doses as low as 5 mg daily have been demonstrated in a human PET imaging study.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem<sup>®</sup> is a trademark of Actinogen Medical.

### **Disclaimer**

This announcement and attachments may contain certain "forward-looking statements" that are not historical facts; are based on subjective estimates, assumptions and qualifications; and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements should be considered "at-risk statements" - not to be relied upon as they are subject to known and unknown risks, uncertainties and other factors (such as significant business, economic and competitive uncertainties / contingencies and regulatory and clinical development risks, future outcomes and uncertainties) that may lead to actual results being materially different from any forward looking statement or the performance expressed or implied by such forward looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Actinogen Medical does not undertake any obligation to revise such statements to reflect events or any change in circumstances arising after the date hereof, or to reflect the occurrence of or non-occurrence of any future events. Past performance is not a reliable indicator of future performance. Actinogen Medical does not make any guarantee, representation or warranty as to the likelihood of achievement or reasonableness of any forward-looking statements and there can be no assurance or guarantee that any forward-looking statements will be realised.

**ACTINOGEN MEDICAL ENCOURAGES ALL CURRENT INVESTORS TO GO PAPERLESS BY REGISTERING THEIR DETAILS WITH THE DESIGNATED REGISTRY SERVICE PROVIDER, AUTOMIC GROUP.**



## Oral Xanamem<sup>®</sup> (emestedastat)

*Controlling brain cortisol to slow progression in Alzheimer's disease and treat depression: enrolling pivotal Phase 2b/3 trial in Alzheimer's*

ASX SMIDCaps conference

26 March 2025

# Disclaimer



- This presentation has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.
- This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Actinogen, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Actinogen and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Actinogen is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Actinogen securities.
- Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Actinogen its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.
- The information presented in this presentation is subject to change without notice and Actinogen does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.
- This presentation is not for general distribution or third party reliance or use.
- This presentation contains certain budget information, forecasts and forward looking statements that are based on the Company’s management’s beliefs, assumptions and expectations and on information currently available to management in respect of which there is NO guarantee of future performance. Such budget information, forecasts and forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Actinogen to be materially different from the results or performance expressed or implied by such forward looking statements. These risks and uncertainties include, but are not limited to the performance of Actinogen in its clinical trials including whether its technology proves to be a safe and effective treatment, market penetration, competition from any other similar products, intellectual property risks (including securing rights in technology and patents) and global economic conditions. Furthermore, Actinogen’s research, product development, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. There is no guarantee that Actinogen will obtain the required approvals, licences and registrations from the relevant authorities in jurisdictions in which it operates. Actinogen or others could identify product and efficacy issues relating to the safety of our technology. Accordingly, all forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the political and economic environment in which Actinogen will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. There is no guarantee that Actinogen will achieve its stated objectives/milestones, that any of its forecasts will be met or that forward looking statements will be realised. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.
- Neither Actinogen nor any other entity or person in or associated with Actinogen guarantee any return (whether capital or income) or generally the performance of Actinogen or the price at which its securities may trade. Any investment in Actinogen is subject to investment risks including the possibility of loss of capital invested and no return of income or payment of any dividends.
- To the maximum extent permitted at law, Actinogen and all of its representatives, directors, officers, partners, employees or professional advisers (Parties) exclude all direct and indirect liability arising out of or in connection with any use or reliance of the information contained or described within this presentation. Other than to the extent required by law (and only to that extent), the Parties do not make any representation or give any assurance, guarantee or warranty (express or implied) as to, nor assume any responsibility or liability for, the authenticity, origin, validity, accuracy, suitability or completeness of, or any errors in or omissions from, any information, statement or opinion contained in this presentation or any accompanying, previous or subsequent material or presentation.

# Corporate snapshot



## ASX-listed company founded in 2014

- Market Cap ~\$100 million
- **Cash balance of \$22.9 million at Dec 31 2024 provides runway to at least mid 2026**
- Conducted three phase 1 (Australia) and four phase 2 trials (Australia, US and UK)



## Key shareholders

- Biotech Value Fund (BVF) ~6%
- **CEO Steve Gourlay ~5% (including via ~\$2 million invested personally)**
- Top 20 ex BVF & Gourlay ~23%



## Phase 2b/3-stage clinical programs are the “sweet spot” for partnering

- **Alzheimer’s disease phase 2b/3 ongoing – interim Q4 2025, final results H2 2026**
- **Major depressive disorder phase 2a completed – seeking non-dilutive funding for phase 2b**
- Type C meeting with FDA to discuss approval requirements for AD Q2-3 2025

# Neuroscience is hot for late-stage programs

**M&A Ph2**  
**Principia<sup>1</sup>/Sanofi**  
**MS, Immunol.**  
**\$3.7B 2020**

**M&A Ph3**  
**Karuna/BMS**  
**Schizophrenia**  
**\$14B 2023**

**M&A Ph2/3**  
**Cerevel/Abbvie**  
**Schizophrenia**  
**\$8.7B 2023**

**License Ph2**  
**PTC/Novartis**  
**Huntington's**  
**\$2.9B 2024**

**M&A Ph2**  
**Longboard/  
Lundbeck**  
**seizures**  
**\$2.9B 2024**

**License Ph1**  
**Voyager/Novartis**  
**Rare neuro.**  
**\$1.9B 2024**

1. Dr Gourlay was founding Chief Medical Officer, designing all clinical programs other than the MS phase 2

# Experienced board and management team

## Board of Directors



**Dr. Geoff Brooke**  
Chairman  
MBBS; MBA



**Dr. Steven Gourlay**  
CEO & MD  
MBBS; FRACP; PhD; MBA



**Mr. Malcolm McComas**  
Non-Executive Director  
BEC, LLB; FAICD; SF Fin



**Dr. George Morstyn**  
Non-Executive Director  
MBBS; PhD; FRACP CD



**Dr. Nicki Vasquez**  
Non-Executive Director  
PhD



## Management Team



**Dr. Steven Gourlay**  
CEO & MD



**Dr. Dana Hilt**  
Chief Medical Officer  
MD



**Will Souter**  
Chief Financial Officer  
BComm, LLB



**Andrew Udell**  
Chief Commercial Officer  
MBA



**Cheryl Townsend**  
VP Clinical Operations  
RN, M Health Law



**Fujun Li**  
Head of Manufacturing  
PhD



**Michael Roberts**  
Head of IR & Comms  
B.Ec (Hons), CPA, FFIN



# Xanamem is now in advanced stages of development



## Novel 11 $\beta$ -HSD1 cortisol control mechanism, oral, attractive safety profile

- Brain cortisol has long been proposed as a pathogenic mechanism in Major Depressive Disorder (MDD) and Alzheimer's (AD)
- Unique brain-penetrant tissue cortisol synthesis inhibitor that leaves adrenal cortisol synthesis unaffected
- Approximately **400 people** treated to date with excellent safety profile and low drug interaction risk



## Positive phase 2 clinical data de-risk clinical program

- **Disease-modifying activity on CDR-SB** in phase 2a trial in biomarker-positive Alzheimer's patients
- **Phase 2a MDD trial showing clinically & statistically significant activity - benefits across multiple endpoints**
- Positive data from both trials read through to other indications in psychiatry and the dementias



## Patent/data protection and advanced manufacturing

- **Composition of matter protection** to 2031, and 2036 with extensions in major markets, newer patents in process
- **Data exclusivity protects Xanamem data** from use by others for 5 to 10 years from approval e.g. 10 years in EU
- **Manufacturing process scaled up and patented**, contractors Asymchem (China) & Catalent (US)



## Large clinical and commercial opportunities

- **No other brain-penetrant cortisol control molecules are in development, first 11 $\beta$ -HSD1 inhibitor awarded INN name<sup>1</sup>**
- Anti-depressant market is currently ~\$20 billion, with major opportunities for novel mechanisms & better-tolerated drugs
- Alzheimer's market likely to be \$20 billion by 2030, with major opportunity for a safe & effective oral agent

1. Xanamem's International Nonproprietary Name (INN), emestedastat, was awarded by a naming committee of the World Health Organization: "-stedastat" chosen for the first time for all 11 $\beta$ -HSD1 inhibitors



# Xanamem controls cortisol by inhibition of 11 $\beta$ -HSD1<sup>1</sup>

Controlling brain cortisol<sup>2</sup> has potential durable benefits

## *Reduction of “stress response” in brain*

**RAPID** changes in kinases, cell function, neurotransmitters over hours to days lead to short-term “low stress” settings



**“Lower stress” shorter term e.g.**

- Reducing inflammation
- Improving neurotransmitter balance
- Decreasing cell death

**SLOW** changes in gene expression and protein synthesis over days to weeks lead to durable “low stress” settings




**“Lower stress” longer term e.g.**

- Improving neural circuitry
- Generating new brain cells
- Ideal receptor configurations

# Human PET study shows full target engagement

Other 11 $\beta$ -HSD1 enzyme inhibitors have not achieved adequate brain levels



Xanamem extensively binds to the 11 $\beta$ -HSD1 enzyme throughout the brain, with high post-treatment effects (absence of color) after 7 days at all doses, slightly less at a 5 mg dose.

This is consistent with full hormonal pharmacodynamic activity seen in clinical trials with doses as low as 5 mg.

Journal of Alzheimer's Disease 97 (2024) 1463–1475  
 Brain 11-Hydroxysteroid Dehydrogenase Type 1 Occupancy by Xanamem™  
 Assessed by PET in Alzheimer's Disease and Cognitively Normal Individuals  
 Victor L. Villemagne, Vincent Dor, Lee Chong, Michael Kassiou, Rachel Mulligan,  
 Azadeh Feizpour, Jack Taylor, Miriam Roesner, Tamara Miller and Christopher C. Rowe

# Alzheimer's disease



Strong cortisol control scientific rationale to address huge unmet medical need

## Rationale

- Cortisol levels are elevated in brain fluid in early AD
- Chronic corticosteroid treatment leads to hippocampal atrophy and cognitive impairment
- Elevated cortisol levels are associated with clinical progression
- Alzheimer's disease mouse model: 30–60% inhibition of 11 $\beta$ -HSD1 provides full neuroprotection
- AD Phase 2a trial shows slowed disease progression in biomarker-positive patients
- **Safe & effective oral therapy is "holy grail"**

## Growing Alzheimer's Disease market – U.S.

Large, unsatisfied and growing market




# Anti-amyloid therapy modestly slows AD progression

Ideally patients with AD would not worsen on treatment at all

Worsening of  
CDR-SB  
over 18 months




Worse  
performance



Drugs targeting other mechanisms like Xanemem are needed

# Xanamem benefit in pTau181-positive AD patients


Phase 2a biomarker study: major slowing of CDR-SB decline (n=34)



Journal of Alzheimer's Disease 100 (2024) 139–150  
 Plasma pTau181 Predicts Clinical Progression in a Phase 2 Randomized Controlled Trial of the 11-HSD1 Inhibitor Xanamem® for Mild Alzheimer's Disease  
 Jack Taylor, Mark Jaros, Christopher Chen, John Harrison and Dana Hilt

# XanaMIA phase 2b/3 trial in Alzheimer's disease

Initial, interim results in Q4 2025, final results H2 2026



Key Inclusion Criteria	Primary Endpoint	Key Secondary Endpoints	Implementation
<ul style="list-style-type: none"> <li>Blood pTau biomarker positive</li> <li>Mild-moderate Alzheimer's by NIA-AA criteria</li> </ul>	<ul style="list-style-type: none"> <li>CDR-SB (functional and cognitive measure)</li> </ul>	<ul style="list-style-type: none"> <li>Cognitive Test Battery (7 cognitive measures well-validated in the Alzheimer's field)</li> <li>Amsterdam Activity of Daily Living (functional measure)</li> </ul>	<ul style="list-style-type: none"> <li>Enrolment at 15 Australian &amp; 20 US sites</li> <li>Interim analysis planned when ~100 people complete 24 weeks</li> </ul>

# Six different datasets validate Xanamem 10mg dose

Data source	Conclusion
Safety data n > 400	No concerning safety signals
Phase 1	Adequate blood levels
Phase 1	Adequate brain fluid levels
Human PET study	High target binding in the brain
Phase 1b	Improved cognition in healthy people
Phase 2a	Slowed Alzheimer's progression (pilot data) <sup>1</sup>
Phase 2a	Improved depression symptoms
Phase 2b/3	Confirmatory Alzheimer's trial in progress

1. Taylor et. al 2024 – positive CDR-SB effect seen in pTau-positive patients

# Building positive momentum



**Evidence of durable benefit on depression from control of brain cortisol validates the Xanamem program** in terms of:

- ✓ “Cortisol control” mechanism of action
- ✓ 10 mg daily proof-of-concept dose being used in Alzheimer’s phase 2b/3 trial
- ✓ 10 mg daily dose is also suitable for next depression trial

**We have high confidence in a positive, disease-modifying outcome in Alzheimer’s disease** over 36 weeks in current XanaMIA trial

- ✓ Interim results Q4 2025
- ✓ Final results H2 2026

Depression is a great alternative indication and anti-depressant effects are also a positive feature for an Alzheimer’s drug label

Company funded to at least mid 2026

Multiple value-add milestones in coming 12 months



# A busy 2025 of milestones and announcements



Milestone	Likely Timing
First patient randomized and treated in US, XanaMIA trial	Q4 24
Meetings at JP Morgan Healthcare conference week, San Francisco	Q1 25
Clinical pharmacology manuscript peer-reviewed publication	Q1 25
FDA Type C meeting for MDD	Q1 25
Clinical Trials Science Forum – focus on commercial planning	Q1 25
100 <sup>th</sup> patient enrolled, XanaMIA trial	Q2 25
XanaCIDD MDD peer-reviewed journal publication	Q3-4 25
ADPD conference AD presentation in Vienna	Q2 25
American Psychiatric Association MDD presentation, Los Angeles	Q2 25
FDA Type C meeting for AD	Q2-3 25
Interim analysis, XanaMIA trial	Q4 25
Full enrolment, 220 patients with AD, XanaMIA trial	Q4 25
AAIC conference AD presentation in Toronto	Q3 25
CTAD conference AD presentation in San Diego	Q4 25

# Actinogen investment highlights



**Novel 11 $\beta$ -HSD1 cortisol control mechanism, oral, attractive safety profile**  
**Potential to be the “holy grail” for Alzheimer’s**



**Positive phase 2a clinical data in two diseases has proven the “cortisol hypothesis”**  
**Phase 2b and 3 trials significantly de-risked**



**Strong patent/data protection**  
**Advanced manufacturing, nonclinical program and clinical pharmacology**



**Large clinical and commercial opportunities – Alzheimer’s will be a \$20 billion market**  
**Phase 2b/3 trial in Alzheimer’s has an interim readout in late 2025 and final results late 2026**

# Appendix



# Key references

Other references see also <https://actinogen.com.au/xanamem>



## 11 $\beta$ -HSD1 inhibition

- Seckl J. 11 $\beta$ -Hydroxysteroid dehydrogenase and the brain: Not (yet) lost in translation. *J Intern Med.* 2024 Jan;295(1):20-37. doi: 10.1111/joim.13741. Epub 2023 Nov 8. PMID:37941106. <https://onlinelibrary.wiley.com/doi/10.1111/joim.13741>
- Cognitive and disease-modifying effects of 11 $\beta$ -hydroxysteroid dehydrogenase type 1 inhibition in male Tg2576 mice, a model of Alzheimer's Disease: Sooy, K., Noble, J., McBride, A., Binnie, M., Yau, J. L. W., Seckl, J. R., Walker, B. R., & Webster, S. P. 2015. *Endocrinology*, 1-12.
- Partial deficiency or short-term inhibition of 11 $\beta$ -hydroxysteroid dehydrogenase type 1 improves cognitive function in aging mice Sooy, K., Webster, S. P., Noble, J., Binnie, M., Walker, B. R., Seckl, J. R., & Yau, J. L. W. 2010. *Journal of Neuroscience*, 30(41), 13867-13872.

## Xanamem clinical trials

- Plasma pTau181 Predicts Clinical Progression in a Phase 2 Randomized Controlled Trial of the 11 $\beta$ -HSD1 Inhibitor Xanamem<sup>®</sup> for Mild Alzheimer's Disease Taylor J, Jaros M, Chen C, Harrison J, Hilt D *J Alz Dis* 2024; 100: 139-150
- Brain 11-Hydroxysteroid Dehydrogenase Type 1 Occupancy by Xanamem<sup>™</sup> Assessed by PET in Alzheimer's Disease and Cognitively Normal Individuals Villemagne VL, Dore V, Chong L, Kassiof M, Mulligan, R, Feizpoura A, Taylor J, Roesner M, Miller T, Rowe CC *J Alz Dis* 2024; 97: 1463-1475
- Selection and early clinical evaluation of the brain-penetrant 11 $\beta$ -hydroxysteroid dehydrogenase type 1 (11 $\beta$ -HSD1) inhibitor UE2343 (Xanamem<sup>™</sup>) Webster, S. P., Ward, P., Binnie, M., Craigie, E., McConnell, K. M., Sooy, K., Vinter, A., Seckl, J.R. & Walker, B. R. 2007. *Bioorganic & medicinal chemistry letters*, 17(10), 2838-2843.
- Various podium and poster presentations on website

## Technical references

- CDR-SB Clinical Dementia Rating Scale – Sum of Boxes is an 18-point, 6-domain measure of patient cognition and function and is a common endpoint used by regulators. Patients in the Xanamem biomarker phase 2a analysis had a baseline of approximately 4 points, similar to that in the donanemab phase 3.
- Cohen, J. (1992). A power primer. *Psychological Bulletin*, 112(1), 155–159. <https://doi.org/10.1037/0033-2909.112.1.155>
- Hengartner MP, Jakobsen JC, Sørensen A, Plöderl M (2020) Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials. *PLOS ONE* 15(2): e0229381. <https://doi.org/10.1371/journal.pone.0229381>

## Alzheimer's disease and cortisol

- Plasma Cortisol, Brain Amyloid- $\beta$ , and Cognitive Decline in Preclinical Alzheimer's Disease: A 6-Year Prospective Cohort Study Pietrzak RH, Laws SM, Lim YY et. al. for the Australian Imaging, Biomarkers and Lifestyle Research Group 2017. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging* 2017; 2(1):45-52
- Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease Starkman, M. N., Giordani, B., Gebarski, S. S., Berent, S., Schork, M. A., & Schteingart, D. E. 1999. *Biol psych*, 46(12), 1595-1602.

## Depression and cortisol

- Ding et. al. *Front. Pharmacol* 2021 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461240/>
- Effect of glucocorticoid and 11 $\beta$ -hydroxysteroid-dehydrogenase type 1 (11 $\beta$ -HSD1) in neurological and psychiatric disorders Dodd S, Skvarc D R, Dean OM, Anderson A, Kotowicz M, Berk M *Int J Neuropsychopharmacol* 2022; 25(5):387-398
- Depression and Hypothalamic-Pituitary-Adrenal Activation: A Quantitative Summary of Four Decades of Research Stetler C, Miller GE *Psychosom Med* 2011; 73(2):114-26

## Market & cost of treatment estimates

- Matthews, K. A., Xu, W., Gaglioti, A. H., Holt, J. B., Croft, J. B., Mack, D., & McGuire, L. C. (2018). Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015–2060) in adults aged  $\geq$  65 years. *Alzheimer's & Dementia*. <https://doi.org/10.1016/j.jalz.2018.06.3063>
- Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. *NEJM*. 2013;368(14):1326-34.
- <https://www.cdc.gov/aging/aginginfo/alzheimers.htm#treated>
- <https://www.nimh.nih.gov/health/statistics/major-depression>
- Symphony Health and ICON plc Company, Metys<sup>®</sup> database full year 2023

## Currencies

- Currencies are in Australian dollars unless otherwise stated

# Selected Glossary 1

- **11 $\beta$ -HSD1** – 11 beta HydroxySteroid Dehydrogenase-1 enzyme. Selectively expressed in brain, liver, adipose.
- **A $\beta$**  – Amyloid beta – a type of amyloid protein associated with Alzheimer’s Disease, 42 and 40 are different forms
- **ACTH** – Adrenocorticotrophic hormone that regulates blood levels of cortisol
- **AD** – Alzheimer’s disease
- **ADAS-Cog** – Alzheimer’s Disease Assessment Score - Cognition
- **ApoE4** – Apoprotein genotype associated with genetic risk of Alzheimer’s Disease
- **ATN** – Amyloid, Tau, Neurodegeneration
- **Clinical Scales** – Measure how a patient feels, performs and functions
- **CDR-SB** – Clinical Dementia Rating “Sum of Boxes” scale measuring cognition and function on an 18-point scale (high worse)
- **CNS** – Central nervous system
- **CSF** – Cerebrospinal fluid
- **CTAD** – Clinical Trials on Alzheimer’s Disease (conference)
- **CTB** – Cognitive Test Battery of computerized tests
- **Double-blind** – Investigators, participants and company do not know who has active vs placebo treatment during a trial
- **EMA** – European Medicines Agency
- **FDA** – US Food & Drug Administration
- **Filamen A** – A protein believed to relate to amyloid toxicity
- **GFAP** – Glial Fibrillary Acidic Protein – a marker of microglial cell activation in the brain
- **IDSST** – International Digit Symbol Substitution Test of cognition

## Selected Glossary 2

- **IQCODE** – Informant Questionnaire on Cognitive Decline in the Elderly
- **MCI** – Mild Cognitive Impairment – memory, executive function deterioration with retained functional abilities
- **MDD** – Major Depressive Disorder
- **MMSE** – Mini Mental State Examination – a 30-point scale of simple questions to assess mental abilities
- **NfL** – Neurofilament Light – a nerve protein in the brain and rest of the body too
- **NIA-AA** – National Institutes of Aging and Alzheimer’s Association
- **NMDA** – A type of receptor for glutamate in the brain
- **NPI** – Neuropsychiatric Inventory to assess psychiatric symptoms
- **NTB** – A Neurologic Test Battery, in this presentation one designed to measure executive function aspects of cognition
- **PET** – Positron Emission Tomography – a type of body scan
- **Placebo controlled** – Non-active treatment for double-blind design
- **p-Tau181 or 217 AD** – Biomarker of phosphorylated Tau protein
- **QPCT** – Glutaminyl-peptide cyclotransferase is an enzyme proposed to create toxic amyloid species
- **RAVLT** – Rey Auditory Visual Learning Test
- **RBANS** – Repeatable Battery for the Assessment of Neuropsychological Status (a test of mental abilities)
- **ROC AUC** – Receiver Operating Curve Area Under the Curve (1.0 ideal) – a type of statistical test to compared two methods of measurement
- **SSRI** – selective serotonin reuptake inhibitor
- **Tau** – A brain protein
- **Ttau** – Total tau levels including both phosphorylated and non-phosphorylated tau

# Contacts

## Michael Roberts

Investor Relations

P: +61 2 8964 7401

M: +61 423 866 231

E. [michael.roberts@actinogen.com.au](mailto:michael.roberts@actinogen.com.au)

## Steven Gourlay

CEO & Managing Director

P: +61 2 8964 7401

E. [steven.gourlay@actinogen.com.au](mailto:steven.gourlay@actinogen.com.au)